Vasopressin: a novel target in heart failure

加压素：心力衰竭的新靶点

• 批准号: nhmrc : 566947
• 负责人: Prof Louise Burrell
• 金额: $ 38.25万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vasopressin-novel-target-heart-failure/82002
• 关键词: Vasopressin; novel; target; heart; failure

Heart failure (HF) is the most common cause of hospital admission in those over 65y, and has significant morbidity and mortality. We need to develop new strategies to treat HF. Plasma vasopressin (AVP) levels are elevated in HF, and may contribute to adverse outcomes. This proposal will assess the utility of blocking the vasopressin V1 and V2 receptors in a rat model of HF. We shall also measure AVP in humans with HF. The results of this work may result in new approaches to treat HF patients.

心力衰竭 (HF) 是 65 岁以上老年人入院的最常见原因，具有显着的发病率和死亡率。我们需要制定治疗心力衰竭的新策略。心力衰竭时血浆加压素 (AVP) 水平升高，可能导致不良后果。该提案将评估在 HF 大鼠模型中阻断加压素 V1 和 V2 受体的效用。我们还将测量心衰患者的 AVP。这项工作的结果可能会带来治疗心力衰竭患者的新方法。